аЯрЁБс>ўџ (*ўџџџ'џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџьЅС'` №П0lbjbjLULU ;.?.?G$џџџџџџЄ$ŒŒŒ8Фи $Р Ж№№№№№№№№? A A A A A A $v hо|e љ№№љљe №№z    љє№№?  љ?    №ф Р‚сІжЬŒэ X ?  0Р  ZE jZ Z 8№0 " B^›№№№e e Џ X№№№Р љљљљ$$$ЄШФ$$$Ш$$$џџџџ PREDICTORS OF MAJOR ADVERSE CARDIAC EVENTS AND OUTCOMES OF RESCUE STENTING WITH IIB/IIIA GLYCOPROTEIN BLOCK IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION D. Fettser1, I. Pershukov3, T. Batyraliev2, L. Petrakova3, I. Lazarev3, J. Ramazanov2, B. Kadyrov2, D. Preobrazhensky3, B. Sidorenko3, Y. Belenkov4 1Regional Clinical Hospital, Lipetsk, Russia, 2Sani Konukoglu Medical Center, Gaziantep, Turkey, 3Central Clinical Hospital Presidential Medical Center, Moscow, Russia, 4Lomonosov's Moscow State University, Moscow, Russia Objectives: The purpose of the study was to estimate the safety and the efficacy of the use of glycoprotein IIb/IIIa inhibitor (tirofiban), on the clinical outcome of the patients with ST-elevation MI during the rescue PCI after the unsuccessful thrombolysis. Methods: The study includes 168 patients in 2006. They were randomized into two groups: I - rescue PCI with stenting, 2 - tirofiban and rescue PCI after the unsuccessful thrombolysis. Only bare-metal stents were implanted during PCI. Results: The estimate of the recent events (0-30 days) showed that in the frequency (group I – 14.7%, group II – 17.2%) and intensity of bleeding there were no significant differences between the groups (p>0.05). In the tirofiban group the distinct growth was recorded in the ejection fraction LV: 7.3% versus 4.5% in group I (p>0.005). Long-term (14.1 months) major adverse cardiac events occurred rarely in group II (10.2% versus 22.1% in group I, p<0.05). Multivariate analysis showed that the cardiogenic shock (OR=6.4, 95% CI: 1.6–18, p=0.005) was an independent predictor of MACE during the 12 months after PCI. Under such conditions only the use of tirofiban during PCI had a significant effect on the decrease of the major adverse cardiac events during the 12 months after PCI (OR=0.19, 95% CI: 0.06–0.57, p=0.004). Conclusions: PCI with IIb/IIIa inhibitors allows reaching the optimal results of the treatment of the patients with STEMI. The IIb/IIIa GP inhibitor improves the long-term outcomes after rescue PCI. The long-term outcomes considerably worsen after cardiogenic shock.     1651, poster, cat: 17  ЁЋЌЏАКЛОПЪЫЮЯйкноцчъыѕіјљњћ        & ' * + 4 5 6 7 d e v • — ˜ п р    FGіяфзяаяШяаяШяаяШяаяШяаяШяаяаяШяаяШяаяШяаяШяЛАЛАЅАЛАЛАšя“я hЧiНhЧiНhЧiНhэ!ЙB*phP8 hЧiНhЈ}ЭB*phhЧiНhэ!ЙB*phhЧiНhЈ}ЭB*H*phhЧiНhЈ}ЭH* hЧiНhЈ}ЭhЧiНhЈ}Э5>*H*\hЧiНhЈ}Э5>*\ hЧiНhэ!ЙhЧiНhэ!Й5\9Ёљ6     T ;FGIJLMOPRSijklїїїїїяяяяясппппппппнппс $1$7$8$H$a$gdЧiН$a$gdЧiН1$7$8$H$Gk§§GHJKMNPQSijklїѓїѓїѓїѓяыѓф hЧiНhэ!Йh$НhTџh ќjh ќU 90&P P:pTџАƒ. АШA!А"А# $ %ААХАХ а†œ@@ёџ@ NormalCJ_H aJmH sH tH DA@ђџЁD Default Paragraph FontRi@ѓџГR  Table Normalі4ж l4жaі (k@єџС(No List 4@ђ4 TџHeader  ЦрР!4 @4 TџFooter  ЦрР!l џџџџЁљ6T;FGIJLMOPRSim˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜@0€€˜@0€€˜@0€€˜@0€€˜0€€Јб00[Ј‘00€Јб00[Ј‘00€Јб00[Ј‘00€Јб00[Ј‘00€˜@0€€Ј‘00, €T;FmjЫ00jЫ00hЫ00@"0Q&QjЫ00€ 001 #####&Gl l k џџgЮ мЭOhЮ ЮOiЮ œЮOм))mо++m8*€urn:schemas-microsoft-com:office:smarttags€City€9*€urn:schemas-microsoft-com:office:smarttags€place€ Lћ js‰•ž …“œУЯпшєџ“œQYКТ3>GGIIJJLMOPRSjmGGIIJJLMOPRSjmFGGIIJJLMOPRShjmGGIIJJLMOPRSjmхq /{Dэ!Й$НЧiНЈ}Э ќTџџ@€ллXЮ ллl@џџUnknownџџџџџџџџџџџџGџ:рAxР џTimes New Roman5€Symbol3& џ:рCxР џArial"ˆ№аhscѕ†Фzѕ‰cѕ† < < !№ЅРxxƒCC2ƒQ№пп№џ?џџџџџџџџџџџџџџџџџџџџџэ!Й2џџ PREDICTORS OF MAJOR ADVERSE CARDIAC EVENTS AND OUTCOMES OF RESCUE STENTING WITH IIB/IIIA GLYCOPROTEIN BLOCK IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION Ramiadminўџр…ŸђљOhЋ‘+'Гй0 ˜ LXht€” ЄА а м ш єчЄPREDICTORS OF MAJOR ADVERSE CARDIAC EVENTS AND OUTCOMES OF RESCUE STENTING WITH IIB/IIIA GLYCOPROTEIN BLOCK IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION Rami Normal.dotadmin4Microsoft Office Word@М e@юŸў”Ь@хz’Ь@˜ПЅжЬ< ўџеЭеœ.“—+,љЎ0 hp„Œ”œ ЄЌДМ Ф qч AtarticaC' ЁPREDICTORS OF MAJOR ADVERSE CARDIAC EVENTS AND OUTCOMES OF RESCUE STENTING WITH IIB/IIIA GLYCOPROTEIN BLOCK IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION Title ўџџџўџџџўџџџ !"#$%&ўџџџ§џџџ)ўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџ РFp ўІжЬ+€1TableџџџџџџџџZWordDocumentџџџџџџџџ;SummaryInformation(џџџџDocumentSummaryInformation8џџџџџџџџџџџџCompObjџџџџџџџџџџџџqџџџџџџџџџџџџџџџџџџџџџџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџ РFMicrosoft Office Word Document MSWordDocWord.Document.8є9Вq